Loading asset research
Aprea Therapeutics Inc. Common stock
APRENasdaq · USD · StocksQuote as of · Exchange session not verified$0.761
-2.44%
Today
APRE
Loading 1D prices…
Market cap
$9.4M
Volume
53.3K
52w high
$1.6952w low
$0.548Company profile
Aprea Therapeutics Inc. Common stock
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
DOYLESTOWN, PA, United States
Employees
8
Fiscal year end
1231
CIK
1781983
Session & valuation
Open$0.78
Previous close$0.78
Day high$0.78
Day low$0.741
30-day avg. volume426.3K
Outstanding shares12.6M
Diluted EPS-$1.93
Latest annual period
P/E (trailing)-0.39
P/E (forward)-2.18
Price / book0.24
Beta1.63
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| IMRNImmuron Limited American Depositary Shares | $9.5M | — | — | -$0.516 | -2.52% | Unrated |
| FBLGFibroBiologics Inc. Common Stock | $9.5M | $0.00 | — | -$0.42 | +2.21% | Buy |
| KALAKALA BIO Inc. Common Stock | $9.2M | $0.00 | — | -$3.31 | -15.00% | Unrated |
| LGVNLongeveron Inc. Class A Common Stock | $8.9M | $1.2M | -1893.58% | -$1.29 | -3.44% | Buy |
| ALZNAlzamend Neuro Inc. Common Stock | $8.8M | $0.00 | — | -$2.63 | +0.55% | Hold |